Department of Surgery, Renal and Pancreas Transplant Unit, University of Padua.
Department of Surgery, Oncology, and Gastroenterology, Urology Clinic, University of Padua.
Arch Ital Urol Androl. 2020 Dec 17;92(4). doi: 10.4081/aiua.2020.4.286.
The aim of the study was to assess results and quality of life after kidney transplant in adult patients with previously bladder augmentation or urinary diversion due to significant lower urinary tract dysfunction.
This cross-sectional study examines the outcome of 19 renal allografts transplanted in patients with augmented bladder or urinary diversion over a ten years period; moreover we submitted SF36 questionnaire to evaluate quality of life of these patients and compared the results with the general population.
Between January 1, 2005 and 31 December 2015 we performed 19/1093 renal transplantations in patients with abnormal lower urinary tract previously treated with bladder augmentation or bladder recycling. Current post-transplant follow-up was 47 months (range 18-188). No patient developed any episode of acute or chronic rejection. Mean serum creatinine after one year from transplant was 102 umol/L. Overall survival is 94.8% at the end of follow-up and graft survival is 89.6%. No significant differences emerged between patients undergoing transplant with lower urinary tract dysfunction and patients without, regarding to recurrent urinary tract infection. There was not statistically significant difference for vitality (p = 0.8088) and mental health (p = 0.8668).
Presence of a previously augmented bladder or other lower urinary tract dysfunction treated in kidney transplant patients doesn't worsen the final outcome. Mental health and the vitality of these patients are similar to the general population.
本研究旨在评估因下尿路功能障碍而接受膀胱扩大术或尿流改道术的成年患者接受肾移植后的结果和生活质量。
本回顾性研究分析了 19 例接受过膀胱扩大术或尿流改道术的患者的 19 个肾移植的结果,这些患者在过去 10 年中接受了肾移植;此外,我们还提交了 SF36 问卷来评估这些患者的生活质量,并将结果与普通人群进行比较。
2005 年 1 月 1 日至 2015 年 12 月 31 日期间,我们对 19/1093 例因异常下尿路而接受过膀胱扩大术或膀胱再循环治疗的患者进行了肾移植。目前的移植后随访时间为 47 个月(范围 18-188)。无患者发生急性或慢性排斥反应。移植后 1 年时的平均血清肌酐为 102 μmol/L。随访结束时,总生存率为 94.8%,移植物生存率为 89.6%。在发生尿路感染方面,有下尿路功能障碍的患者与无下尿路功能障碍的患者之间没有显著差异。在活力(p=0.8088)和心理健康(p=0.8668)方面,差异无统计学意义。
在肾移植患者中,存在先前的扩大膀胱或其他下尿路功能障碍并不会恶化最终结果。这些患者的心理健康和活力与普通人群相似。